Skip to content
Business Times – Lifestyle
Author:
Faron Pharmaceuticals
Inside Information: Faron Announces Encouraging First Overall Survival Data from Frontline Higher-Risk (HR) MDS Patients in the BEXMAB Phase 1/2 Trial
July 27, 2026
Faron Pharmaceuticals Ltd: Holding(s) In Company
July 24, 2026
Faron Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab
July 13, 2026
Faron Pharmaceuticals Ltd: Grant of Options
July 1, 2026
Faron Pharmaceuticals LTD: Holding(s) in Company
June 22, 2026
Faron Pharmaceuticals LTD: Holding(s) in Company
June 17, 2026
Faron Pharmaceuticals LTD: Holding(S) In Company
June 17, 2026
Faron Pharmaceuticals Ltd: Holding(s) in Company
June 15, 2026
Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS
June 15, 2026
Faron Pharmaceuticals Ltd: Holding(s) In Company
June 11, 2026
1
2
3
4
Next Page
→